The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.
about
Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASPersonalized treatment for advanced colorectal cancer: KRAS and beyondAcquired resistance to EGFR-targeted therapies in colorectal cancerGene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerCytohesins/ARNO: the function in colorectal cancer cellsWhere now for anti-EGF receptor therapies in colorectal cancer?Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type statusProspective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximabHER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximabHow many diseases are colorectal cancer?Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer.Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.Methods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1.Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab.Integrating anti-EGFR therapies in metastatic colorectal cancer.Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver.Association between the overexpression of Her3 and clinical pathology and prognosis of colorectal cancer: A meta-analysis
P2860
Q26766535-B092AEB1-7A71-4909-915C-E5DF70ED5CFBQ26822817-5E3F51DF-3FB5-4C3E-9703-3123F5FE8081Q27022741-D465789C-245F-4249-A345-4AAE55E89E4AQ27853108-1B2C2A9D-4B7B-4A98-96B6-740FB61DAC40Q28071772-6BCF6ADA-DA4E-462C-9717-045E2995C497Q28076490-67906F29-A44B-4798-BA0C-3793A4688B08Q28077545-9B393DF3-617F-4F7E-A788-5980C03A05F7Q28540770-18DDCB34-C587-47F5-84D5-BC29E83B1CF0Q31038305-F18FA316-327D-446C-8A7E-BF8BFD07D95DQ35114983-0F7C763B-2B6C-4E13-A89B-7CF8DD96D1FBQ35137474-B9037FD7-B3A8-40CA-8BA6-89CCDB4B8602Q35583697-B6CAC790-9824-4F6B-84E9-27CE7B44EA85Q36020920-4B880BED-2ADE-44F2-BDD5-B23BF76F3FF6Q36207072-B513B813-D5EA-4AFE-B01C-FB27889B1FE5Q36238965-F8F4EE1A-1031-492E-A9A2-23BD5C550161Q37970537-D5738FDB-C023-43D9-808B-7BB366E0A176Q38096413-CD0D558A-9B4F-4527-902F-DE11C340D8E7Q38516244-40DC3963-D7B2-4968-BC47-F4E3BF509634Q38648300-302D7AD3-D856-48C3-8093-D662DB50BF8FQ38709385-525D323C-49E0-488E-8B0E-F07D2FFE48DFQ38869420-0AB683D6-06D5-4E23-9E79-68F9D97FF8F5Q39223563-9D7760A9-8091-43F9-8DF1-7AD94919E19BQ39430066-64E23E57-0F6B-4AC6-931D-C03F2B022662Q43090496-BCFDE43C-0553-4A5A-91D6-95343F1EDF96Q47190268-865DD604-F864-4EC1-B7EC-608790D6359AQ47707557-1AD85C80-0E24-4C34-9182-F9A564A599B5Q53640616-0A04542F-22FF-47AF-8C40-8059BDFDBDBDQ58739568-C3EC57EA-F8B2-4833-839F-D625018F39CA
P2860
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The role of HER-3 expression i ...... ving irinotecan and cetuximab.
@ast
The role of HER-3 expression i ...... ving irinotecan and cetuximab.
@en
type
label
The role of HER-3 expression i ...... ving irinotecan and cetuximab.
@ast
The role of HER-3 expression i ...... ving irinotecan and cetuximab.
@en
prefLabel
The role of HER-3 expression i ...... ving irinotecan and cetuximab.
@ast
The role of HER-3 expression i ...... ving irinotecan and cetuximab.
@en
P2093
P2860
P50
P1433
P1476
The role of HER-3 expression i ...... iving irinotecan and cetuximab
@en
P2093
Alberto Zaniboni
Alessandra Mandolesi
Alessandro Bittoni
Chiara Pierantoni
Eva Galizia
Italo Bearzi
Lucio Giustini
Renato Bisonni
Riccardo Giampieri
Rosa Rita Silva
P2860
P356
10.1634/THEONCOLOGIST.2010-0119
P577
2011-01-06T00:00:00Z